An advisory panel votes to pull Amag’s Makena from the market, but will the US regulator follow through?
More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
A post-mortem of Bristol’s first-line trial suggests that patients’ PD-L1 status should have been taken into consideration, though Roche hopes it too can do without such…
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.
Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.
With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…